ARBUTUS BIOPHARMA (F.K.A TEKMIRA PHARMACEUTICALS) – GLAUCUS RESEARCH
Bonitas Research, 10 November 2014
Tekmira Pharmaceuticals Corp (NASDAQ: TKMR) (“Tekmira” or the “Company”) is a Vancouver-based biopharmaceutical
company focused on developing RNA-interference (“RNAi”) delivery technology using the Company’s proprietary lipid
nanoparticle (“LNP”) delivery platform. In the last three months, Tekmira’s share price has nearly doubled because the U.S. Food and Drug Administration (“FDA”) temporarily lifted a clinical hold on the Company’s anti-Ebola RNAi therapeutic (“TKM Ebola”) to allow the drug’s administration to Ebola infected patients in emergency situations. Continue reading “Article: ARBUTUS BIOPHARMA (F.K.A TEKMIRA PHARMACEUTICALS) – GLAUCUS RESEARCH”
